Passage Bio, INC 8-K filings

Passage Bio has terminated its research collaboration with Gemma Biotherapeutics and exited its Philadelphia office lease, incurring a $2.3 million termination fee.

Passage Bio, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Passage Bio is implementing a significant restructuring, reducing its workforce by approximately 75% to decrease operating expenses as it reviews strategic alternatives.

Passage Bio announced updated interim data from its PBFT02 trial for FTD-GRN, showing reduced brain atrophy and stabilized NfL, but faces FDA requirement for a randomized trial, prompting a strategic review.

Passage Bio announced its full-year 2025 financial results and provided key updates on its clinical programs for frontotemporal dementia and preclinical work for Huntington's disease.

Passage Bio, Inc. reported preliminary unaudited cash of approximately $46 million as of December 31, 2025, extending its cash runway into Q1 2027, alongside positive interim clinical data for its FTD-GRN gene therapy, PBFT02.

Passage Bio reports progress in its upliFT-D clinical trial for FTD-GRN and FTD-C9orf72, aligns with FDA on manufacturing, and extends cash runway into Q1 2027.

Passage Bio, Inc. announced the resignation of Saqib Islam from its Board of Directors and Audit Committee, leading to a reduction in board size.

Passage Bio announced its second quarter 2025 financial results, highlighting progress in its upliFT-D clinical trial for FTD-GRN and extending its cash runway into Q1 2027.

Passage Bio, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, resolving a previous listing deficiency.

Passage Bio, a clinical-stage genetic medicines company, announced a 1-for-20 reverse stock split effective July 14, 2025, aimed at regaining compliance with Nasdaq's minimum bid price requirement.

Passage Bio, Inc. announced updated interim data from its Phase 1/2 upliFT-D clinical trial for PBFT02 in FTD-GRN, showing robust biomarker improvements and outlining plans for a protocol amendment to enhance safety and broaden patient enrollment.

Passage Bio, Inc. announced the outcomes of its 2025 Annual Meeting of Stockholders, including the election of two Class II directors, ratification of KPMG LLP as its independent auditor, and approval for a potential reverse stock split.

Passage Bio announced its Q1 2025 financial results, highlighting progress in its FTD-GRN program and a strengthened manufacturing process.

Passage Bio announced positive interim data from its PBFT02 program in FTD-GRN patients, demonstrating durable progranulin expression and early evidence of improvement in a disease progression biomarker, along with an extended cash runway into the first quarter of 2027.

Passage Bio, Inc. has transferred its stock listing to the Nasdaq Capital Market and received an extension until July 28, 2025, to regain compliance with the minimum bid price requirement.

Passage Bio is restructuring its operations, reducing its workforce by 55%, and transitioning to an outsourced analytical testing model, which extends its cash runway into the first quarter of 2027.

Passage Bio announced encouraging clinical trial progress for its PBFT02 gene therapy, along with a financial update showing a cash runway into Q2 2026.

Passage Bio announced positive preclinical and interim clinical data for its PBFT02 gene therapy, showing significant increases in progranulin levels and a favorable safety profile in patients with frontotemporal dementia with GRN mutations (FTD-GRN).

Passage Bio's PBFT02 gene therapy shows promising interim safety and biomarker data in patients with frontotemporal dementia, demonstrating robust increases in progranulin levels.

Passage Bio has appointed Thomas Kassberg, a seasoned biotech executive, to its Board of Directors and Audit Committee, effective September 10, 2024.

Passage Bio subleased a portion of its laboratory space, leading to an expected impairment charge of $3.5 million to $5.5 million.

Passage Bio announced positive progress in its upliFT-D trial, strategic out-licensing of pediatric programs, and a strong cash position extending operations into Q2 2026.

Passage Bio has been notified by Nasdaq that it no longer meets the minimum bid price requirement for continued listing, triggering a potential delisting process.

Passage Bio has out-licensed three of its pediatric gene therapy programs to Gemma Biotherapeutics, securing upfront payments and extending its cash runway to the end of the second quarter of 2026.

Passage Bio announced positive feedback from the FDA regarding their proposal to expand the upliFT-D trial of PBFT02 to include frontotemporal dementia patients with C9orf72 gene mutations.

Passage Bio held its 2024 Annual Meeting of Stockholders on May 21, 2024, where two Class I directors were elected and the appointment of KPMG LLP as the company's independent auditor was ratified.

Passage Bio announced positive interim data from its upliFT-D trial showing consistent elevation of CSF progranulin levels in FTD-GRN patients, along with a financial update indicating a cash runway into Q4 2025.

Passage Bio announced its 2023 financial results, highlighted progress in its FTD-GRN clinical trial, and appointed Kathleen Borthwick as Chief Financial Officer.

Passage Bio has regained compliance with Nasdaq's minimum bid price requirement after its stock price closed above $1.00 for 10 consecutive business days.